Skip to main content

Table 3 Correlations of changes between first two visits (Δ = first visit – second visit) in levels of BAFF or anti-Jo-1 antibodies with change of disease activity and their association with prior daily dose of glucocorticoids given at initial assessment

From: Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

 

Change in BAFF

Change in anti-Jo-1

GC daily dose

n

r

p

n

r

p

n

r

p

Δ BAFF

–

–

–

44

0.18

0.25

43

0.31

0.04a

Δ CK

44

0.75

< 0.0001***

42

0.24

0.13

41

0.23

0.14

Δ Myoglobin

36

0.64

< 0.0001***

34

0.44

0.009

33

0.35

0.04

Δ ALT

45

0.52

0.0003**

43

0.31

0.04

42

0.33

0.03

Δ AST

43

0.63

< 0.0001***

41

0.54

0.0003**

40

0.30

0.05

Δ CRP

42

0.32

0.04

40

0.33

0.04

39

0.27

0.10

Δ Muscle VAS

39

0.33

0.04

37

−0.12

0.49

39

0.28

0.08

Δ Global VAS

39

0.38

0.02

37

−0.05

0.78

39

0.38

0.02

Δ Skeletal VAS

39

0.45

0.004**

37

0.1

0.56

39

0.06

0.72

Δ Cutaneous VASb

12

0.64

0.03a

11

−0.03

0.92

12

0.38

0.22

Δ Pulmonary VASc

30

−0.01

0.94

28

−0.30

0.12

30

0.42

0.02a

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase, CRP C-reactive protein, GC glucocorticoids, VAS visual analogue scale
  2. p = p value; **alfa = 0.01 (0.001 after Bonferroni correction); ***alfa = 0.001 (0.0001 after Bonferroni correction).
  3. aNo multiple testing correction applicable
  4. bEvaluated within patients with dermatomyositis
  5. cEvaluated within patients with interstitial lung disease
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us